ACR Contrast Allergy Premedication Protocol for Imaging Centers: Guide Published
Oct 23, 2026
New guidance from ContrastConnect explains how the 2026 ACR contrast allergy recommendations impact premedication decisions, contrast-agent selection, and patient safety, with virtual radiologist supervision supporting imaging centers’ coverage needs.
Las Vegas, United States, October 23, 2026 /PressCable/ -- ContrastConnect has published a guide explaining the 2026 ACR contrast allergy premedication guidelines and their implications for imaging centers. The resource covers updates to steroid premedication, contrast-agent substitution based on reaction severity, and requirements for radiologist supervision during contrast administration.
More details can be found at https://www.contrast-connect.com/blog-post/acr-contrast-allergy-premedication-protocol-2026-guidelines-explained.
The new recommendations follow a 2025 joint consensus statement from the American College of Radiology (ACR) and the American Academy of Allergy, Asthma & Immunology (AAAAI). For patients with prior mild immediate reactions to iodinated contrast, routine steroid premedication is no longer recommended. Instead, the guidance supports substituting the documented inciting agent, making accurate records of reactions and contrast products essential for clinical decisions.
According to the ContrastConnect guide, premedication may be considered alongside agent substitution for moderate reactions. For patients with severe reaction histories, the guidance recommends considering imaging without iodinated contrast first. If no suitable alternative exists, premedication and switching agents when feasible may be appropriate.
When premedication is indicated for scheduled exams, the standard oral regimen includes prednisone at 13, 7, and 1 hour before contrast, plus diphenhydramine one hour before the procedure. Urgent cases may use an accelerated five-hour IV hydrocortisone regimen with diphenhydramine. A Radiology study found breakthrough reaction rates of 2.5% with the accelerated regimen versus 2.1% with the 13-hour oral protocol, meeting noninferiority criteria. Regimens shorter than four to five hours lack supporting evidence unless a life-threatening situation makes delay impossible.
The guide also reviews risk factors, including prior contrast reactions, asthma, and significant atopy. Shellfish allergy and topical iodine exposure are not independent risk factors. Documenting the specific contrast agent in the electronic health record helps teams assess substitution options.
Implementing these recommendations also requires imaging centers to consider radiologist availability during contrast administration. Effective January 1, 2026, the Centers for Medicare & Medicaid Services (CMS) permanently recognizes real-time, interactive audio-video presence as meeting direct supervision requirements in applicable outpatient settings, where permitted by state law.
To address radiologist coverage needs, ContrastConnect offers virtual contrast supervision through licensed radiologists, with immediate availability and documentation for CMS review. The company reports supervising more than 75,000 hours of contrast exams and managing over 130 contrast reactions monthly, offering imaging centers an alternative to onsite radiologist staffing.
For more information, visit https://www.contrast-connect.com/
Contact Info:
Name: Dor Shoshan
Email: Send Email
Organization: ContrastConnect
Address: Las vegas, Las Vegas, NV 89109, United States
Website: https://www.contrast-connect.com/
Source: PressCable
Release ID: 89207199
If there are any deficiencies, discrepancies, or concerns regarding the information presented in this press release, we kindly request that you promptly inform us by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team is committed to addressing any identified issues within 8 hours to guarantee the delivery of accurate and reliable content to our esteemed readers.
More News
Civil servant who juggled five jobs says he was 'surprised' to be charged with fraud
Kashim Chowdhury denied being dishonest when not telling employers he had other jobs.
Republicans Cut Taxes to Win the Midterms. It May Not Work Out.
Among the stakes in next month’s election is the long-running question of whether tax cuts can shape how people vote.
Fearing Mass A.I. Layoffs, Some in Congress Eye Ways to Aid Workers
A bill to bolster the nation’s unemployment insurance program reflects the concern — and the risks — in Washington.
A.I. and New Rules for Accounting Are an Opportunity for Start-Ups
Pennylane, a French company, has gained market share in its home country by helping accountants work with clients. It’s aiming to expand internationally.
Volvo Shares Plunge as China Ambitions Fade for Western Carmakers
The Swedish automaker plans to cut another 2,500 jobs, joining competitors in offering a gloomy view of the world’s biggest car market.
What is PHP and why did it spark a global cyber-security scramble?
AI uncovered long-hidden programming flaws, triggering a rare global cyber-security response.
Island inflation rate rises to 3%, figures show
The rising cost of food and alcohol drives an increase in the inflation rate, figures show.
Earnings limit of up to £140K for first-time buyers loan scheme
The Your First Home scheme will offer government-backed loans for those buying new-builds in England.
A Tech Rotation Roils the Markets, Again
Investors are bracing for a one-two punch: rising oil prices and concerns about the soaring costs of the artificial intelligence buildout.
A Simple Way to Benefit From Rising Rates: Buy Money Market Funds
While higher interest rates are a complication for stocks and bonds, they are an unequivocal boon if you just want to park some cash and make a little money, our columnist says.
Trump’s Plan to Import More Ground Beef Is Falling Short
About a fifth of the 300,000 metric tons of lean beef trimmings have come through customs, six weeks through a program designed to lower prices.
Melanoma Vaccine Ushers in New Hope for Cancer Patients
Beyond melanoma, scientists are studying cancer vaccines for glioblastoma, pancreatic cancer and more.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.